Achaogen is a clinical-stage company that discovers, develops and seeks to commercialize novel antibacterials to treat multi-drug resistant (MDR), gram-negative infections. The company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin has been granted FDA Breakthrough Therapy designation.
Antibiotic resistance is an increasing public health problem in hospitals and the community that represents a large unmet need. In the U.S., at least 2 million people become infected with bacteria that are resistant to antibiotics each year, according to the Centers for Disease Control and Prevention (CDC). CDC surveillance data indicates that the rate of carbapenem resistance in Klebsiella species increased from 1.6% to 10.4% in the hospital setting in the United States between 2001 and 2011. The CDC has characterized CRE as “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action.” CRE leads to mortality rates of up to 50% in patients with bloodstream infections.
Foresite Capital believes that Achaogen’s novel antibacterials have the potential to play a significant role in the treatment of MDR gram- negative infections.